On Tuesday, Zymeworks BC Inc (NASDAQ: ZYME) opened higher 4.49% from the last session, before settling in for the closing price of $18.47. Price fluctuations for ZYME have ranged from $9.03 to $19.50 over the past 52 weeks.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 15.81%. Company’s average yearly earnings per share was noted 47.33% at the time writing. With a float of $73.13 million, this company’s outstanding shares have now reached $74.85 million.
Zymeworks BC Inc (ZYME) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Zymeworks BC Inc is 3.44%, while institutional ownership is 102.22%. The most recent insider transaction that took place on May 15 ’25, was worth 565,847. In this transaction Director of this company bought 49,502 shares at a rate of $11.43, taking the stock ownership to the 17,877,989 shares. Before that another transaction happened on May 19 ’25, when Company’s Director bought 5,919 for $11.78, making the entire transaction worth $69,738. This insider now owns 17,883,908 shares in total.
Zymeworks BC Inc (ZYME) Recent Fiscal highlights
If we go through the results of last quarter, which was made public on 9/30/2024, the company posted -0.39 earnings per share (EPS) for the quarter, besting the agreed prediction (set at -0.41) by 0.02. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.24 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 47.33% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 5.70% during the next five years compared to 15.81% growth over the previous five years of trading.
Zymeworks BC Inc (NASDAQ: ZYME) Trading Performance Indicators
Check out the current performance indicators for Zymeworks BC Inc (ZYME). In the past quarter, the stock posted a quick ratio of 7.69. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 11.90.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.98, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -0.87 in one year’s time.
Technical Analysis of Zymeworks BC Inc (ZYME)
Compared to the last year’s volume of 0.57 million, its volume of 1.33 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 57.55%.
During the past 100 days, Zymeworks BC Inc’s (ZYME) raw stochastic average was set at 97.50%, which indicates a significant increase from 93.17% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.82 in the past 14 days, which was higher than the 0.62 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.36, while its 200-day Moving Average is $13.71. Nevertheless, the first resistance level for the watch stands at $19.66 in the near term. At $20.01, the stock is likely to face the second major resistance level. The third major resistance level sits at $20.61. If the price goes on to break the first support level at $18.71, it is likely to go to the next support level at $18.11. Now, if the price goes above the second support level, the third support stands at $17.76.
Zymeworks BC Inc (NASDAQ: ZYME) Key Stats
There are currently 75,166K shares outstanding in the company with a market cap of 1.46 billion. Presently, the company’s annual sales total 76,300 K according to its annual income of -122,700 K. Last quarter, the company’s sales amounted to 48,730 K and its income totaled 2,320 K.
